Anhand von konkreten Projekten zeigen die Spezialistinnen und Spezialisten die Anwendung von digitalen Tools und Verfahren und wie Kunden konkret davon profitieren. Zum Beispiel in Form von Inhalten, die die Zielgruppe wirklich erreichen. Die Baubranche steht ja in Teilen noch vor Digitalisierungswellen, die andere Branchen hinter sich haben. Der Neubau des Bundeshauses wird greifbar und real.
SBSa biotechnology company, today announced it has successfully developed commercial levels of apolipoprotein AI and its variant apolipoprotein AI Milano collectively referred to as Apo AI in safflower seed lines. Apo AI is a major component of "good cholesterol" or HDL high density lipoprotein which naturally removes atheroscleroticplaque from arteries.
This achievement is a key milestone for SemBioSys'cardiovascular drug development program. Unlike statins, the lead drug class in this market, which halt plaque build-up, clinical results from Apo AI have actually demonstrated significant plaque reduction.
We believe manufacturing capacity and cost are major commercialization issues for pharmaceutical companies developing Apo AI. Today's announcement demonstrates that safflower seed is an enabling production vehicle for Apo AI with the scale and economics necessary to allow for the commercialization of this potentially transformative therapy," said Andrew Baum, President and CEO of SemBioSys Genetics Inc.
With the recent setbacks reported with other HDL modulators like torcetrapib and AGI, Apo AI is clearly positioned at the forefront of cardiovascular disease therapy see Nature Dec 14; pages As an enabling manufacturing solution, we believe our Apo AI development program represents an attractive partnership opportunity for companies developing such cardiovascular therapies and with these results we will initiate formal partnering activities.
SemBioSys' technology addresses protein extraction and purification as well as bulk protein production.
The Company has also produced authentic human insulin in safflower, which is expected to enter clinical trials in early SemBioSys intends to scale-up production of safflower-produced Apo AI and perform the necessary preclinical work in in order to initiate clinical trials in About Apo AI Apo AI is a developmental-stage cardiovascular therapy, designed to rapidly stabilize and diminish atherosclerotic plaque for the prevention and treatment of cardiovascular disease.
Apo AI is the major apolipoprotein associated with HDL, commonly referred to as "good cholesterol", which naturally removes plaque from arteries. High dosing up to 20 grams per course of patient treatment coupled with a large patient population is expected to drive volume demand of several tonnes of Apo AI per year, underscoring the value of a highly scalable plant manufacturing solution.
About Cardiovascular Disease Atherosclerotic cardiovascular diseases are the leading cause of mortality in developed nations and by are projected to become the leading cause of mortality worldwide.
The call will be hosted by Mr. A live audio webcast of the conference call will be available through www. Please connect to this website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be needed to hear the webcast.
A replay of the webcast will be available for 90 days at www. A replay of the conference call will also be available by telephone on July 12, through July 19, The Company's lead candidate is recombinant human insulin produced in the plant host safflower, to serve the rapidly expanding global diabetes market and to supply insulin for inhalation and other alternative insulin delivery technologies.
The Company is also developing Apo AI, a next generation cardiovascular drug. In addition to its pharmaceutical products SemBioSys is developing a series of non-pharmaceutical products addressing animal and aquaculture health, nutritional oils and human topical markets.
Forward-looking statements reflect the Company's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. The Company undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable Canadian securities laws.
Issues - Atherosclerotic cardiovascular diseases CVD are the leading causeof mortality in developed nations and byare projected to become the leading cause of mortality worldwide. Benefits - Targets the leading cause of global mortality through the treatment And prevention of cardiovascular disease.
About Apo AI Apo AI is a development-stage cardiovascular therapy, designed to rapidly stabilize and diminish atherosclerotic plaque for the prevention and treatment of cardiovascular disease.
Apo AI is the major apolipoprotein associated with high density lipoprotein HDLcommonly referred to as "good cholesterol", which naturally removes plaque from arteries.
Apo AI appears to have specific potential in the acute treatment of patients presenting with acute coronary syndrome or a recent stroke event, who are at high risk of a recurrence due to unstable plaque. Recombinant Apo AI is currently produced at high-cost using microbial fermentation.
This process presents severe capacity limitations and endotoxin contamination issues. SemBioSys' plant-based technology overcomes these manufacturing barriers and is expected to bring significant cost and scale benefits to Apo AI production.
Until recently, torcetrapib, a first-in-class cholesteryl ester transfer protein CETP inhibitor developed by Pfizer, was viewed as the forerunner small molecule drug designed to elicit atherosclerotic regression.
After promising early and mid-stage clinical trials, Pfizer recently terminated their pivotal Phase III trials of torcetrapib due to increased rates of angina, heart failure and death in the treatment population. Unlike torcetrapib, which increased serum HDL through dysregulation of lipoprotein metabolism, Apo AI uses the natural mechanism of HDL particles to promote the body's innate reverse cholesterol transport and is not expected to be obstructed by the adverse events observed with torceptrapib.
The clinical setbacks reported with other HDL modulators like torcetrapib and AGI clearly position Apo AI at the forefront of the cardiovascular therapeutic candidates see Nature Dec 14; pages About Cardiovascular Disease According to the World Health Organization, atherosclerotic cardiovascular diseases are the leading cause of mortality in developed nations and byare projected to become the leading cause of mortality worldwide.
Acute coronary syndrome ACS is associated with physiological conditions characterized by insufficient blood flow to the heart and describes individuals that present with either acute myocardial infarction heart attack or unstable angina. SemBioSys believes there is a significant clinical need for pharmacological therapies that rapidly stabilize and diminish atherosclerotic plaque for the prevention and treatment of ACS and stroke.schwebte Sawiris in Andermatt ein und erklärte seinen Plan.
Es gab keinen Wettbewerb, wir wurden faul.“ Die Teilnahme an der Reise wurde unterstützt von Schweiz Tourismus. The Doing Business database now covers seven sets of indicators covering countries for two years.
Annual updates will follow. Topics include registering a business, hiring and firing labor, getting credit, enforcing a contract, transferring property, investor protection, and bankruptcy. C M T Marketingplan3 1. CMT – City Management und Tourismus Chemnitz GmbH MARKETINGPLAN 2. Einleitung Die CMT – City Management und Tourismus Chemnitz GmbH stellt mit der vorliegenden Broschüre ihre mittelfristige Marketingplanung vor.
Auf den geeigneten Dächern und Fassaden der Schweiz könnte mit Fotovoltaikmodulen rund die Hälfte des heutigen Strombedarfs der Schweiz in der Jahresbilanz produziert werden.
Es gibt gute Gründe, wenigstens einen Teil dieses Potenzials zu nutzen. Als Business Angel und Coach erläutert Andreas Müller, Mitgründer der Unternehmensberatung Opitz, Müller& Partner, worauf er bei Gründungen achtet. In dem lebhaften Gespräch mit Prof.
Faltin stehen vor allem das Geschäftsmodell, der Gründer, der Business Plan Wettbewerb und das Gründen aus Komponenten im Vordergrund. Definitions of Israel, synonyms, antonyms, derivatives of Israel, analogical dictionary of Israel (German) Israel-Tourismus im Aufwind.
Business solution. Improve your site content. Add new content to your site from Sensagent by XML. Crawl products or adds. Get XML access to reach the best products.
Index images and define metadata.